21 recruiting, 19 completed, 18 unknown, 9 not yet recruiting. 74 Phase 1, 36 Phase 2.
Follow sintilimab: new trials by email Literature Review of sintilimab trials Research Report on sintilimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma SYS6090 Injection + Bevacizumab Injection, SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection, Bevacizumab Injection + Sintilimab Injection - HCC - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 288 | 2026-09-30 | 2026-08-12 |
| A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma BRII-5395, Sintilimab, Bevacizumab - Advanced HBV-Related Hepatocellular Carcinoma | Phase 1 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 21 | 2026-08-12 | 2026-08-31 |
| Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet) IBI310+ sintilimab + bevacizumab, IBI310+ sintilimab, sintilimab + bevacizumab - Resectable Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 90 | 2026-07-20 | 2026-07-20 |
| HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion HSK41959, Sintilimab, Pemetrexed + Cisplatin /Carboplatin - Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC) | Phase 1 | Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | 258 | 2026-07-01 | 2026-07-14 |
| Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors IBI3005, Sintilimab, Bevacizumab biosimilar - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 282 | 2026-06-01 | 2026-05-28 |
| Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS Sintilimab - HIV, AIDS | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Public Health Clinical Center | 50 | 2026-05-01 | 2026-05-12 |
| Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma FOLFOX regimen, Immunotherapy, targeted therapy - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | BinYong Liang | 100 | 2026-04-30 | 2026-04-13 |
| GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study GV20-0251, Sintilimab - Head and Neck Squamous Cell Carcinoma HNSCC | Phase 1 | Recruiting | West China Hospital | 9 | 2026-04-01 | 2026-03-25 |
| Study of ABO2102 in KRAS-Mutated Solid Tumors ABO2102 Injection, Sintilimab injection - Advanced / Metastatic Solid Tumor | Phase 1 | Recruiting | Suzhou Abogen Biosciences Co., Ltd. | 101 | 2026-03-24 | 2026-04-06 |
| IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer IBI343, Sintilimab, Oxaliplatin - Gastric Cancer | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 55 | 2025-06-02 | 2026-08-18 |
| Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma individualized anti-tumor new antigen iNeo-Vac-R01 injection, Gemcitabine + cisplatin (GP), Sintilimab injection - Advanced Intrahepatic Cholangiocarcinoma | Phase 1 / Phase 2 | Recruiting | Zhejiang University | 30 | 2025-04-09 | 2025-05-04 |
| Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer. individualized anti-tumor new antigen iNeo-Vac-R01 injection, mFOLFIRINOX Treatment Regimen, Sintilimab injection - Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable | Phase 1 / Phase 2 | Not yet recruiting | Zhejiang University | 30 | 2025-04-01 | 2025-03-21 |
| Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer. individualized anti-tumor new antigen iNeo-Vac-R01 injection, Gemcitabine + Capecitabine, Sintilimab injection - Pancreatic Cancer Resectable | Phase 1 / Phase 2 | Not yet recruiting | Zhejiang University | 60 | 2025-04-01 | 2025-03-21 |
| Clinical Study on Efficacy and Safety of IBI310, Bevacizumab Combined With Sintilimab in Advanced HCC IBI310(1mg/kg), sintilimab, bevacizumab - Hepatocellular Carcinoma | Phase 1 | Recruiting | Shanghai Zhongshan Hospital | 50 | 2025-03-06 | 2026-11-17 |
| Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma Sintilimab and Linperlisib Combination Treatment - Extranodal Natural Killer/T Cell Lymphoma | Phase 1 | Recruiting | Sun Yat-sen University | 12 | 2025-02-21 | 2025-03-13 |
| mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer Anlotinib combined with Sintilimab - Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | Fujian Provincial Hospital | 29 | 2024-12-23 | 2025-01-07 |
| Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer Bortezomib Injection, Sintilimab, mFOLFIRINOX - Pancreas Cancer | Phase 1 / Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 63 | 2024-11-15 | 2025-01-10 |
| Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer Propranolol hydrochloride, Sintilimab, Chemotherapy - Non Small Cell Lung Cancer, Propranolol | Phase 1 / Phase 2 | Recruiting | Second Xiangya Hospital of Central South University | 118 | 2024-11-13 | 2026-11-19 |
| A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) AK112, Cadonilimab, AK127 - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | Akeso | 280 | 2024-09-24 | 2026-03-04 |
| Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC Sintilimab, IBI110, Paclitaxel - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Fudan University | 27 | 2024-06-26 | 2025-02-25 |
Showing 20 of 74. Sign in to see all of them.
Carcinoma, Hepatocellular (9) · Carcinoma, Non-Small-Cell Lung (8) · Stomach Neoplasms (5) · Neoplasms (3) · Colorectal Neoplasms (2) · Pancreatic Neoplasms (2) · Acquired Immunodeficiency Syndrome (1) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Melanoma (1) · Meningeal Carcinomatosis (1) · Neoplasm Metastasis (1)
Innovent Biologics (Suzhou) Co. Ltd. (22) · Fudan University (4) · Shanghai Zhongshan Hospital (4) · Sun Yat-sen University (3) · West China Hospital (3) · Zhejiang University (3) · Beijing Tsinghua Chang Gung Hospital (2) · Ruijin Hospital (2) · Sichuan University (2) · Akeso (1) · BinYong Liang (1) · CSPC Megalith Biopharmaceutical Co.,Ltd. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chinese PLA General Hospital (1) · First Affiliated Hospital of Zhejiang University (1)
China (67) · Australia (2) · United States (2) · France (1) · Germany (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Ying Cheng (2) · You Lu, MD (2) · Zhen Zhang, M.D, PH.D (2) · Ba Yi (1) · Darren Shafren (1) · Fang Meiyu (1) · Gong Li, MD (1) · Guo Hongqian (1) · Guo Wei (1) · Ji Zhu, M.D. (1) · Jin Li (1) · Jun Zhang (1) · Kangshun Zhu, Dr. (1)
PMID 20728210, PMID 24094768, PMID 25240821, PMID 26884585, PMID 30718072, PMID 32372672, PMID 32795349, PMID 33070260, PMID 34659886, PMID 34877867, PMID 35352512, PMID 35647908, PMID 35747712, PMID 35995696, PMID 36505833, PMID 36628898, PMID 37828033, PMID 38214075, PMID 39134346, PMID 39806128, PMID 40046248, PMID 41005780, PMID 41423492, PMID 41513419, PMID 41540424, PMID 42736273